AOD-9604 Research Guide: Identity, Literature, Analysis and Documentation
Research use only. StarBio products are supplied strictly for in-vitro laboratory research by qualified professionals. They are not for human or veterinary use, not for diagnostic or therapeutic use, and have not been evaluated by the FDA. This guide covers identity, documentation and handling only. It is not usage guidance.
AOD-9604 is a 16-residue peptide: residues 177 to 191 of human growth hormone with one extra tyrosine added at the N-terminus. It contains two cysteines joined in a disulfide bridge, which closes most of the molecule into a loop and gives its certificate one specific thing to prove. This page collects the identity data, the research areas the literature covers, the analytical points raised by the disulfide, and the report on file.
Identity
| Name | AOD-9604 (Tyr-hGH 177-191) |
|---|---|
| Type | Synthetic 16-residue analogue of the C-terminal fragment of human growth hormone |
| CAS number | 221231-10-3 |
| Molecular weight | 1815.1 g/mol |
| Formula | C78H123N23O23S2 |
| Sequence | Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (Cys7-Cys14 disulfide) |
| Length | 16 amino acids |
Origin and history
The peptide came from the laboratory of Frank Ng at Monash University in Melbourne, which spent the 1990s studying fragments of the C-terminal region of growth hormone. It was developed commercially in Australia by Metabolic Pharmaceuticals, went through clinical trials in the 2000s, and its development as a pharmaceutical was then discontinued. Since then it has appeared in the literature mainly in two places: a small number of animal studies, and anti-doping chemistry, where laboratories publish methods to detect it.
What the literature covers
The references on file for this compound span several research areas. They are listed here as areas of study, not as results.
- Metabolic studies in mice. Three papers from 2000 and 2001 on the fragment and lipid metabolism in obese mice [1, 2, 3], and a 2004 drug profile [5].
- Analytical and anti-doping chemistry. Detection and in vitro metabolism (2015) [6], characterisation of a seized preparation (2014) [9] and a 2017 review of mass spectrometry in sports drug testing [10].
- Joint model. A 2015 study in a rabbit osteoarthritis model [8].
- Reviews. Two obesity pharmacotherapy reviews (2006, 2012) [11, 12] and two 2026 reviews that survey peptides in orthopaedics and sport [4, 7].
The anti-doping papers are the most useful to an analyst, because they describe how the molecule behaves in a mass spectrometer and what it breaks down into.
Analytical notes
The disulfide between the cysteines at positions 7 and 14 is what the certificate has to establish. The bridged form is 2 Da lighter than the reduced form with two free thiols, and material that has formed disulfides between molecules instead of within one appears as a dimer at twice the mass. Mass spectrometry of the correct product gives a monoisotopic 907.9 for the doubly protonated molecule and 605.6 for the triply protonated one.
The peptide has no methionine and no tryptophan. Its ultraviolet absorbance at 280 nm is weak, coming from a single tyrosine, so purity is measured at 210 to 220 nm. With two arginines it is basic and soluble in water. In solution the disulfide can rearrange at alkaline pH, so solutions are best kept slightly acidic and cold.
Storage and stability
- Lyophilized powder
- Store at -20 °C
- Protect from light
- Avoid repeated freeze-thaw cycles
- In solution: 2-8 °C, short term
Documentation for StarBio lots
Every StarBio lot is analysed by an independent laboratory. The table lists the report on file for this compound.
| Variant | Laboratory / report | HPLC purity | Labelled / measured | Tested | |
|---|---|---|---|---|---|
| AOD-9604 5 mg | Medutest WWB-5AD-4095 | 99.38% | 5 mg | Feb 7, 2026 | report |
The report on file is for a different vial size from the 10 mg sold today. A report for the current size will be listed here when it is published.
Current certificates are in the COA Library; the verify-lot form connects an order to its batch record.
References
- Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone research, 2000, PMID 11146367.
- Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2001, PMID 11673763.
- The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology, 2001, PMID 11713213.
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, 2026, PMID 41490200.
- AOD-9604 Metabolic. Current opinion in investigational drugs (London, England : 2000), 2004, PMID 15134286.
- Detection and in vitro metabolism of AOD9604. Drug testing and analysis, 2015, PMID 25208511.
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports medicine (Auckland, N.Z.), 2026, PMID 41966639.
- Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Annals of clinical and laboratory science, 2015, PMID 26275694.
- Identification and characterization of peptide drugs in unknown pharmaceutical preparations seized by the Belgian authorities: case report on AOD9604. Drug testing and analysis, 2014, PMID 24976118.
- Human sports drug testing by mass spectrometry. Mass spectrometry reviews, 2017, PMID 26213263.
- Current updates in the medical management of obesity. Recent patents on endocrine, metabolic & immune drug discovery, 2012, PMID 22435392.
- Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors. Obesity (Silver Spring, Md.), 2006, PMID 16931496.
Product page: AOD-9604. Related guides: Igf 1 Lr3 research guide, what 99% purity means, storing lyophilized peptides.
For laboratory research use only. Not for human or veterinary use.
Questions about AOD-9604
What is AOD-9604?
AOD-9604 is a hGH C-terminal fragment analog (Tyr-hGH 177-191): 16 residues, molecular weight 1815.1 g/mol, CAS number 221231-10-3. It is supplied for in vitro laboratory research only. This guide covers identity, documentation and handling, not use.
Is AOD-9604 the same as Tyr-hGH(177-191) and hGH fragment 177-191 analogue?
AOD-9604 is also listed as Tyr-hGH(177-191) and hGH fragment 177-191 analogue. On a certificate or vial label, the CAS number (221231-10-3) and the sequence identify the material regardless of which name is used.
What are the CAS number, formula and molecular weight of AOD-9604?
AOD-9604 has CAS number 221231-10-3, molecular formula C78H123N23O23S2 and molecular weight 1815.1 g/mol. Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (Cys7-Cys14 disulfide). Identity of each StarBio batch is confirmed by mass spectrometry on the laboratory report.
Is StarBio's AOD-9604 independently tested?
Yes. The current AOD-9604 batch was tested by Medutest (Medutest report WWB-5AD-4095): 99.38% purity by HPLC, tested Feb 7, 2026. The report is on file in the COA library (report page).
How should AOD-9604 be stored?
Lyophilized powder; Store at -20 °C; Protect from light; Avoid repeated freeze-thaw cycles; In solution: 2-8 °C, short term. StarBio ships it as sealed lyophilized powder.
Where can I buy AOD-9604 for laboratory research?
StarBio sells AOD-9604 as 10 mg at $89.99, shipped tracked from Florida to all 50 US states. StarBio does not ship internationally. Buyers must be qualified researchers or institutions aged 21 or older, buying for in vitro laboratory work.
New reports and guides, by email
A short note when a new laboratory report is published, when a compound returns to stock, and when a new guide goes up. Nothing else. Leave whenever you like.
For laboratory research use only. No dosing or protocol content is ever sent.

